Urology Today.net

Site updated at Thursday, 12 May 2016

Common Urological Problems

New target for prostate cancer treatment discovered by Keck Medicine of USC researchers

  • - Urology / Nephrology News
  • Feb 21, 2015
  • Comments
  • Viewed: 3241
Tags: |

Keck Medicine of the University of Southern California (USC) scientists have found a promising new therapeutic target for prostate cancer. The findings offer evidence that a newly discovered member of a family of cell surface proteins called G-protein coupled receptors (GPCRs) promotes prostate cancer cell growth. The protein, GPR158, was found while the researchers were looking for new drug targets for glaucoma.

Prostate cancer is the second most common cancer in American men, after skin cancer, according to the American Cancer Society (ACS). The ACS projects more than 27,000 deaths from prostate cancer in 2015 and is the second leading cause of cancer death in American men, behind lung cancer. One man in seven will be diagnosed with prostate cancer during his lifetime.

“When a prostate cancer tumor is in its early stages, it depends on hormones called androgens to grow,” said Nitin Patel, Ph.D., research scientist at the Institute for Genetic Medicine at the Keck School of Medicine of USC, and corresponding author on the research. “Eventually it progresses to a more lethal form, called castration-resistant prostate cancer (CRPC), and is resistant to drugs that block androgen receptors. We found that GPR158, unlike other members of the GPCR family, is stimulated by androgens, which in turn stimulates androgen receptor expression, leading to tumor growth.”

The team also discovered that GPR158 is associated with neuroendocrine transdifferentiation (NED) of epithelial prostate tumor cells, which plays a critical role in development of resistance to contemporary androgen receptor-target therapies.

The scientists found that prostate cancer patients with elevated GPR158 expression experienced recurrence of prostate cancer. The GPR158 protein is a likely target for new prostate cancer drugs.

The researchers used a conditional Pten knockout mouse model of prostate cancer in collaboration with Keck School of Medicine of USC researchers Mitchell Gross, Chun-Peng Liao and Pradip Roy-Burman.

The team is now exploring the molecular pathways involved in the functional role of GPR158 in NED in the development of CRPC and exploring GPR158-targeted antibody therapeutics.


The study, titled “Expression and Functional Role of Orphan Receptor GPR158 in Prostate Cancer Growth and Progression,” will be published Feb. 18, 2015 in the peer-reviewed journal PLOS ONE.

The research was produced by the laboratory led by senior author M. Elizabeth Fini. Other USC researchers contributing to the study include Tatsuo Itakura, Shinwu Jeong, Ebrahim Zandi, Susan Groshen, Jacek Pinski and Gerhard A. Coetzee.

Funding for the research was provided by National Institutes of Health grant R01-EY09828 and The Robert E. and May R. Wright Foundation.


Leslie Ridgeway
.(JavaScript must be enabled to view this email address)


University of Southern California - Health Sciences


Bookmark and Share

Post a comment [ + Comment here + ]

There are no comments for this entry yet. [ + Comment here + ]

Your details

* Required field

Please enter the word you see in the image below:

Comments are moderated by our editors, so there may be a delay between submission and publication of your comment. Offensive or abusive comments will not be published.

section of nephrology1 - low-grade prostate cancer2 - long-term dialysis1 - fallopian tubes1 - hormone-deprivation therapy1 - boston university school of medicine1 - pancreatic cancer2 - hesitancy2 - mammogram1 - renal function2 - heart surgery2 - miscellaneous diseases1 - srtr1 - mortality risk1 - american society nephrology1 - smoking1 - end-stage kidney disease3 - prognostic indicator1 - renal anemia1 - prostate inflammation1 - intravenous injection1 - the american society of nephrology3 - urinary reflux1 - kidney care1 - respiration1 - mesonephric duct1 - prostatic calculi1 - active surveillance1 - tgen1 - bone metastases3 -